{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T11:58:54Z","timestamp":1701259134591},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,7,10]],"date-time":"2006-07-10T00:00:00Z","timestamp":1152489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,7,10]],"date-time":"2006-07-10T00:00:00Z","timestamp":1152489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1007\/s10637-006-9244-8","type":"journal-article","created":{"date-parts":[[2006,7,10]],"date-time":"2006-07-10T21:15:26Z","timestamp":1152566126000},"page":"537-542","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study"],"prefix":"10.1007","volume":"24","author":[{"given":"James H.","family":"Doroshow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian F.","family":"Issell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taral","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick W.","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen J.","family":"Yost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,7,10]]},"reference":[{"key":"9244_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","volume":"53","author":"A Jemal","year":"2003","unstructured":"Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5\u201326","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"9244_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10120-002-0205-4","volume":"5","author":"JS Macdonald","year":"2002","unstructured":"Macdonald JS (2002) Advances in the therapy of gastric cancer. Gastric Cancer 5(Suppl 1):35\u201340","journal-title":"Gastric Cancer"},{"key":"9244_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/1097-0142(19950901)76:5<715::AID-CNCR2820760502>3.0.CO;2-3","volume":"76","author":"JL Berenberg","year":"1995","unstructured":"Berenberg JL, Tangen C, Macdonald JS, Hutchins LF, Natale RB, Oishi N, Guy JT, Fleming TR (1995) Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study. Cancer 76:715\u2013719","journal-title":"Cancer"},{"key":"9244_CR4","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1023\/A:1013129315036","volume":"12","author":"CD Blanke","year":"2001","unstructured":"Blanke CD, Haller DG, Benson AB, Rothenberg ML, Berlin J, Mori M, Hsieh YC, Miller LL (2001) A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol 12:1575\u20131580","journal-title":"Ann Oncol"},{"key":"9244_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/annonc\/mdg106","volume":"14","author":"DY Kim","year":"2003","unstructured":"Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, Kim NK (2003) Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 14:383\u2013387","journal-title":"Ann Oncol"},{"key":"9244_CR6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/sj.bjc.6601226","volume":"89","author":"CH Kohne","year":"2003","unstructured":"Kohne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Di Betta D, Jacques C, Wilke HJ (2003) Irinotecan is active in chemonaive patients with metastatic gastric cancer: A phase II multicentric trial. Br J Cancer 89:997\u20131001","journal-title":"Br J Cancer"},{"key":"9244_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00001813-200206000-00003","volume":"13","author":"DG Haller","year":"2002","unstructured":"Haller DG, Misset JL (2002) Docetaxel in advanced gastric cancer. Anticancer Drugs 13:451\u2013460","journal-title":"Anticancer Drugs"},{"key":"9244_CR8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11912-003-0112-9","volume":"5","author":"JY Tsai","year":"2003","unstructured":"Tsai JY, Safran H (2003) Status of treatment for advanced gastric carcinoma. Curr Oncol Rep 5:210\u2013218","journal-title":"Curr Oncol Rep"},{"key":"9244_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00000421-200302000-00008","volume":"26","author":"SM Gadgeel","year":"2003","unstructured":"Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, Philip PA (2003) Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 26:37\u201341","journal-title":"Am J Clin Oncol"},{"key":"9244_CR10","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1989.7.9.1310","volume":"7","author":"P Preusser","year":"1989","unstructured":"Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ, Buente H (1989) Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310\u20131317","journal-title":"J Clin Oncol"},{"key":"9244_CR11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.1992.10.4.541","volume":"10","author":"D Kelsen","year":"1992","unstructured":"Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 10:541\u2013548","journal-title":"J Clin Oncol"},{"key":"9244_CR12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.1997.15.1.368","volume":"15","author":"AF Sobrero","year":"1997","unstructured":"Sobrero AF, Aschele C, Bertino JR (1997) Fluorouracil in colorectal cancer\u2013a tale of two drugs: Implications for biochemical modulation. J Clin Oncol 15:368\u2013381","journal-title":"J Clin Oncol"},{"key":"9244_CR13","first-page":"377","volume":"4","author":"YM Rustum","year":"1985","unstructured":"Rustum YM (1985) Selective modulation of 5-fluorouracil action in patients with colorectal carcinoma. Chemioterapia 4:377\u2013382","journal-title":"Chemioterapia"},{"key":"9244_CR14","first-page":"3964","volume":"42","author":"DS Martin","year":"1982","unstructured":"Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW (1982) High-dose 5-fluorouracil with delayed uridine \u201crescue\u201d in mice. Cancer Res 42:3964\u20133970","journal-title":"Cancer Res"},{"key":"9244_CR15","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1016\/0006-2952(92)90142-6","volume":"43","author":"LD Nord","year":"1992","unstructured":"Nord LD, Stolfi RL, Martin DS (1992) Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of antitumor activity with dosage and FUra incorporation into RNA. Biochem Pharmacol 43:2543\u20132549","journal-title":"Biochem Pharmacol"},{"key":"9244_CR16","first-page":"745","volume":"70","author":"CJ Van Groeningen","year":"1986","unstructured":"Van Groeningen CJ, Leyva A, Kraal I, Peters GJ, Pinedo HM (1986) Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 70:745\u2013750","journal-title":"Cancer Treat Rep"},{"key":"9244_CR17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/jnci\/81.2.157","volume":"81","author":"CJ Van Groeningen","year":"1989","unstructured":"Van Groeningen CJ, Peters GJ, Leyva A, Laurensse E, Pinedo HM (1989) Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. J Natl Cancer Inst 81:157\u2013162","journal-title":"J Natl Cancer Inst"},{"key":"9244_CR18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnci\/83.6.437","volume":"83","author":"CJ Van Groeningen","year":"1991","unstructured":"Van Groeningen CJ, Peters GJ, Nadal JC, Laurensse E, Pinedo HM (1991) Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst 83:437\u2013441","journal-title":"J Natl Cancer Inst"},{"key":"9244_CR19","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1200\/JCO.1997.15.4.1511","volume":"15","author":"DP Kelsen","year":"1997","unstructured":"Kelsen DP, Martin D, O\u2019Neil J, Schwartz G, Saltz L, Sung MT, von Borstel R, Bertino J (1997) Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. J Clin Oncol 15:1511\u20131517","journal-title":"J Clin Oncol"},{"key":"9244_CR20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1200\/JCO.2000.18.1.167","volume":"18","author":"M Hidalgo","year":"2000","unstructured":"Hidalgo M, Villalona-Calero MA, Eckhardt SG, Drengler RL, Rodriguez G, Hammond LA, Diab SG, Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O\u2019Neil JD, von Borstel R, Von Hoff DD, Rowinsky EK (2000) Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J Clin Oncol 18:167\u2013177","journal-title":"J Clin Oncol"},{"key":"9244_CR21","first-page":"235a","volume":"16","author":"JH Doroshow","year":"1997","unstructured":"Doroshow JH, Carroll M, Leong L, Johnson D, Chow W, Hamasaki V, Margolin K, Morgan RJ, Raschko J, Shibata S, Somlo G, Tetef M, Yen Y, Synold T, Newman E, ter Veer A, Longmate J, von Borstel R, Louie A (1997) Dose escalation trial of 5-FU, leucovorin (LV), and the oral uridine analog PN401 in patients (pts) with metastatic colorectal cancer (cc) who have failed prior 5-FU therapy. Proc Amer Soc Clin Oncol 16:235a","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"9244_CR22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/02841869609098503","volume":"35","author":"PA Larsson","year":"1996","unstructured":"Larsson PA, Carlsson G, Gustavsson B, Graf W, Glimelius B (1996) Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects. Acta Oncol 35:207\u2013212","journal-title":"Acta Oncol"},{"key":"9244_CR23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF02785872","volume":"16","author":"Y Novik","year":"1999","unstructured":"Novik Y, Ryan LM, Haller DG, Asbury R, Dutcher JP, Schutt A (1999) Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: Results of ECOG 5282. Med Oncol 16:261\u2013266","journal-title":"Med Oncol"},{"key":"9244_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF00874433","volume":"11","author":"JL Berenberg","year":"1993","unstructured":"Berenberg JL, Tangen C, Macdonald JS, Barlogie B, Laufman LR (1993) VM-26 in gastric cancer. A Southwest Oncology Group study. Invest New Drugs 11:333\u2013334","journal-title":"Invest New Drugs"},{"key":"9244_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1023\/A:1005899720463","volume":"15","author":"JK Benedetti","year":"1997","unstructured":"Benedetti JK, Burris HA III, Balcerzak SP, Macdonald JS (1997) Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study. Invest New Drugs 15:261\u2013264","journal-title":"Invest New Drugs"},{"key":"9244_CR26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00000421-199512000-00005","volume":"18","author":"SK Williamson","year":"1995","unstructured":"Williamson SK, Tangen CM, Maddox AM, Spiridonidis CH, Macdonald JS (1995) Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study. Am J Clin Oncol 18:484\u2013487","journal-title":"Am J Clin Oncol"},{"key":"9244_CR27","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1200\/JCO.1987.5.8.1150","volume":"5","author":"SG Arbuck","year":"1987","unstructured":"Arbuck SG, Douglass HO Jr, Trave F, Milliron S, Baroni M, Nava H, Emrich LJ, Rustum YM (1987) A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma. J Clin Oncol 5:1150\u20131156","journal-title":"J Clin Oncol"},{"key":"9244_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/clpt.1980.156","volume":"28","author":"JM Collins","year":"1980","unstructured":"Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE (1980) Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routes. Clin Pharmacol Ther 28:235\u2013246","journal-title":"Clin Pharmacol Ther"},{"key":"9244_CR29","first-page":"4667","volume":"44","author":"S Madajewicz","year":"1984","unstructured":"Madajewicz S, Petrelli N, Rustum YM, Campbell J, Herrera L, Mittelman A, Perry A, Creaven PJ (1984) Phase I\u2013II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 44:4667\u20134669","journal-title":"Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9244-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-006-9244-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9244-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-006-9244-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:18:57Z","timestamp":1678558737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-006-9244-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,10]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["9244"],"URL":"https:\/\/doi.org\/10.1007\/s10637-006-9244-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,10]]},"assertion":[{"value":"10 July 2006","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}